You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 15, 2025

Emergent Manufacturing Operations Baltimore Llc Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Biologic Drugs for Emergent Manufacturing Operations Baltimore Llc

Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Emergent Manufacturing Operations Baltimore Llc N/A raxibacumab Injection 125349 10,111,968 2032-02-15 Patent claims search
Emergent Manufacturing Operations Baltimore Llc N/A raxibacumab Injection 125349 10,562,974 2033-03-13 Patent claims search
Emergent Manufacturing Operations Baltimore Llc N/A raxibacumab Injection 125349 10,590,182 2035-02-24 Patent claims search
Emergent Manufacturing Operations Baltimore Llc N/A raxibacumab Injection 125349 10,703,800 2036-04-26 Patent claims search
Emergent Manufacturing Operations Baltimore Llc N/A raxibacumab Injection 125349 10,953,106 2036-02-15 Patent claims search
Emergent Manufacturing Operations Baltimore Llc N/A raxibacumab Injection 125349 10,975,112 Patent claims search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source
Similar Applicant Names
Companies are sometimes listed under multiple names.
This search can help find similar names.

Biotech Competitive Landscape Analysis: Emergent Manufacturing Operations Baltimore LLC – Market Position, Strengths & Strategic Insights

In the dynamic world of biotechnology, Emergent Manufacturing Operations Baltimore LLC has established itself as a significant player. This article delves into the company's market position, strengths, and strategic insights, providing a comprehensive analysis of its competitive landscape.

The Evolution of Emergent Manufacturing Operations Baltimore LLC

Emergent Manufacturing Operations Baltimore LLC, a subsidiary of Emergent BioSolutions Inc., has been at the forefront of biopharmaceutical manufacturing for years. The company's journey began with a focus on developing and manufacturing medical countermeasures for biological and chemical threats[1]. Over time, it has expanded its capabilities and market presence, becoming a key player in the biotech manufacturing sector.

Market Position in the Biotech Manufacturing Landscape

Emergent's Baltimore facility has played a crucial role in the company's overall market position. The 87,000 square foot manufacturing site offered clinical and commercial non-viral aseptic fill-finish services on four fill lines, including lyophilization, formulation development, and support services[7]. This capability positioned Emergent as a versatile player in the biopharmaceutical manufacturing space.

Key Strengths and Capabilities

  1. Diverse Portfolio: Emergent's Baltimore facility contributed to the company's diverse portfolio of medical countermeasures, ranging from vaccines to therapeutics[3].

  2. Expertise in Biodefense: The company's focus on biodefense has given it a unique edge in addressing critical public health challenges[3].

  3. State-of-the-Art Manufacturing: The Baltimore facility was equipped with advanced technology for efficient large-scale production[3].

  4. Strategic Partnerships: Emergent has established collaborations with government agencies and international organizations, enhancing its market position[3].

Recent Strategic Moves and Their Impact

Sale of Baltimore-Camden Facility

In a significant move, Emergent BioSolutions announced the sale of its Baltimore-Camden manufacturing site to Bora Pharmaceuticals for approximately $30 million in August 2024[7].

"This milestone is a significant step forward in our multi-year plan to stabilize, turnaround, and transform Emergent," said Joe Papa, President and CEO at Emergent[7].

This strategic decision aligns with Emergent's multi-year plan to create a more customer-focused, leaner, and flexible organization while improving overall profitability and reducing debt[7].

Restructuring and Workforce Changes

As part of its restructuring efforts, Emergent announced plans to reduce its workforce by about 300 employees across all areas of the company and eliminate approximately 85 job openings[5]. This move is expected to result in annual cost savings of about $80 million[5].

Competitive Landscape and Market Challenges

Key Competitors

Emergent operates in a highly competitive landscape, with several major players vying for market share:

  1. Sanofi: A global pharmaceutical company with a strong presence in vaccines and infectious disease treatments[3].

  2. GlaxoSmithKline (GSK): Another pharmaceutical giant with significant resources in vaccine development[3].

  3. Merck & Co.: Known for innovative products and research in the healthcare industry[3].

  4. Johnson & Johnson: A diversified healthcare company with a robust portfolio of products, including vaccines and treatments for infectious diseases[3].

Challenges in the Biotech Manufacturing Sector

  1. Regulatory Compliance: The industry faces stringent regulatory requirements, as evidenced by the FDA warning letter received by Emergent's Camden site in 2022[4].

  2. Technological Advancements: Keeping pace with rapid technological changes in biopharmaceutical manufacturing is crucial for maintaining competitiveness.

  3. Market Volatility: The biotech sector is subject to rapid changes in demand, particularly in response to global health crises.

Strategic Insights and Future Prospects

Pivot Away from CDMO Business

Emergent's sale of the Baltimore facility signifies a strategic shift away from its Contract Development and Manufacturing Organization (CDMO) business[4]. This move allows the company to focus on its core competencies and potentially explore new growth areas.

Focus on Innovation and R&D

To maintain its competitive edge, Emergent is likely to increase its focus on research and development, particularly in areas of unmet medical needs and emerging health threats[3].

Global Expansion Opportunities

With an increasing global demand for medical countermeasures, Emergent has opportunities to expand its presence in international markets[3].

Environmental, Social, and Governance (ESG) Considerations

Emergent has demonstrated a commitment to ESG principles, as outlined in its 2021 ESG Report[6]. This focus on sustainability and responsible business practices can enhance the company's reputation and appeal to socially conscious investors and partners.

Key Takeaways

  1. Emergent Manufacturing Operations Baltimore LLC has been a significant player in biotech manufacturing, with strengths in biodefense and diverse product portfolio.

  2. The recent sale of the Baltimore-Camden facility marks a strategic shift towards a leaner, more focused organization.

  3. Restructuring efforts, including workforce reductions, aim to improve profitability and reduce debt.

  4. The company faces stiff competition from global pharmaceutical giants but maintains unique strengths in specialized areas.

  5. Future strategies likely include increased focus on innovation, global expansion, and adherence to ESG principles.

FAQs

  1. Q: What was the primary function of Emergent's Baltimore-Camden facility? A: The facility offered clinical and commercial non-viral aseptic fill-finish services, including lyophilization and formulation development.

  2. Q: Why did Emergent sell its Baltimore-Camden facility? A: The sale aligns with Emergent's multi-year plan to create a more customer-focused, leaner organization and improve overall profitability.

  3. Q: How much did Bora Pharmaceuticals pay for the Baltimore-Camden facility? A: Bora Pharmaceuticals acquired the facility for approximately $30 million.

  4. Q: What are Emergent's main competitive advantages in the biotech industry? A: Emergent's strengths include its expertise in biodefense, diverse product portfolio, and strategic partnerships with government agencies.

  5. Q: How is Emergent addressing environmental and social responsibilities? A: Emergent has demonstrated commitment to ESG principles, as outlined in its 2021 ESG Report, focusing on sustainability and responsible business practices.

Sources cited: [1] https://business.maryland.gov/news/emergent-biosolutions-plans-baltimore-facility-expansion/ [3] https://canvasbusinessmodel.com/blogs/growth-strategy/emergent-biosolutions-growth-strategy [4] https://www.fiercepharma.com/manufacturing/emergent-pivoting-away-cdmo-sells-baltimore-site-acquisitive-bora-30m [5] https://www.fiercepharma.com/pharma/emergent-biosolutions-cut-300-employees-shutter-2-facilities-restructuring-launched-under [6] https://www.emergentbiosolutions.com/wp-content/uploads/2022/11/2021-Emergent-ESG-Report.pdf [7] https://www.biospace.com/emergent-biosolutions-finalizes-sale-of-baltimore-camden-manufacturing-site-to-bora-pharmaceuticals

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.